EUVIMEDEUVIMED entdecken
Open Access

Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage

Qianjin Guo iD, Sooyeon Lee, Neali Armstrong, Brian Lim, Rebecca C Schugar, David Tomz, Haixia Xu, Anzel Zhen, Leor Needleman, Electron Kebebew, Justin P Annes

Endocrine-Related Cancer · 01.03.2026 · 33 (3)

DOI: 10.1530/erc-25-0397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 19.02.2026. Verfasst von Qianjin Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Succinate Dehydrogenase, DNA Damage, Naphthoquinones, Imidazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The hereditary pheochromocytoma and paraganglioma (hPPGL) syndrome, caused by germline mutations in succinate dehydrogenase (SDHx) genes, predisposes individuals to pheochromocytomas (Pheo), paragangliomas (PGLs), renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GISTs). Notably, tumors with succinate dehydrogenase subunit B (SDHB) deficiency demonstrate an increased metastatic risk and current systemic treatments remain only palliative. Hence, discovering novel therapeutic avenues to improve SDHB cancer prognosis is an urgent need. Here, we leveraged human SDHB-deficient UOK269 RCC cells (SDHB-KO) and isogenic SDHB-reconstituted control cells (SDHB-WT) to discover SDH-dependent mitochondria-directed cytotoxic agents. Given the reduced ATP-generating capacity of SDHB-KO cells, we hypothesized that they would be uniquely sensitive to futile cycle induction with mitochondrial ionophores. Indeed, ionophores exhibited preferential cytotoxicity toward SDHB-KO cells. However, the mitochondria-directed chemotherapeutic compound Ym155 demonstrated more potent and dramatic preferential cytotoxicity toward SDHB-KO cells. Importantly, SDH-dependent cytotoxicity of Ym155 was validated in multiple cell models, including primary human pheochromocytoma cells, a mouse pheochromocytoma (MPC) cell line and primary SDHB-deficient mouse kidney cells. Notably, genetic evidence of Ym155 synthetic lethality with SDHB deficiency was buttressed in additional cell models using two chemical inhibitors of SDH enzyme activity. Mechanistically, SDH deficiency sensitized cells to Ym155-induced DNA damage. Strikingly, SDH-dependent Ym155 sensitivity was recapitulated by inhibition of the histone demethylase KDM4, a downstream consequence of SDH deficiency. In summary, accumulation of succinate in SDH-deficient tumors inhibited KDM4 activity, impaired DNA repair and yielded enhanced susceptibility to Ym155-induced reactive oxygen species (ROS) generation. The identified intrinsic susceptibilities of SDHB-deficient cancers have the potential to be therapeutically leveraged.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Succinate DehydrogenaseDNA DamageNaphthoquinonesImidazolesHumansCell Line, TumorAnimalsMicePheochromocytoma

Stichwörter der Autor:innen

DNA damageYm155mitochondrial redox imbalancepheochromocytomas and paragangliomas (PPGLs)renal cell carcinomasuccinate dehydrogenasesynthetic lethality

Substanzen

Succinate DehydrogenaseNaphthoquinonesImidazolesSDHB protein, human

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Stanford University, Stanford, California, USA.
  • Department of Surgery and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.
  • Endocrine Oncology Program, Stanford University, Stanford, California, USA.
  • Chemistry, Engineering, and Medicine for Human Health (ChEM-H) Institute, Stanford University, Stanford, California, USA.

ORCID-Profile: Qianjin Guo

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Guo, Q., Lee, S., Armstrong, N., Lim, B., Schugar, R. C., Tomz, D., Xu, H., Zhen, A., Needleman, L., Kebebew, E., & Annes, J. P. (2026). Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage. Endocrine-Related Cancer, 33(3). https://doi.org/10.1530/erc-25-0397

Vancouver

Guo Q, Lee S, Armstrong N, Lim B, Schugar RC, Tomz D, et al. Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage. Endocrine-Related Cancer. 2026;33(3). doi:10.1530/erc-25-0397

BibTeX
@article{Guo2026,
  author = {Guo, Qianjin and Lee, Sooyeon and Armstrong, Neali and Lim, Brian and Schugar, Rebecca C and Tomz, David and Xu, Haixia and Zhen, Anzel and Needleman, Leor and Kebebew, Electron and Annes, Justin P},
  title = {Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  volume = {33},
  number = {3},
  doi = {10.1530/erc-25-0397}
}
Kostenlos starten →